Having found no new cases of progressive multifocal leukoencephalopathy in a completed safety review of Tysabri patients, Biogen Idec Inc. and Elan Corp. plc said they hope to get the multiple sclerosis drug back on the market, with regulatory paperwork to be filed in the fall. (BioWorld Today) Read More
